Pharmaceutical Products Companies By Current Asset

Current Asset
Current AssetEfficiencyMarket RiskExp Return
1MGNX MacroGenics
342.38 M
(0.31)
 4.59 
(1.43)
2CAMP CAMP4 THERAPEUTICS PORATION
298.77 M
 0.01 
 10.80 
 0.15 
3DNLI Denali Therapeutics
281.74 M
(0.10)
 4.54 
(0.48)
4VERA Vera Therapeutics
237.64 M
(0.17)
 3.93 
(0.67)
5ME 23Andme Holding Co
212.32 M
(0.13)
 11.72 
(1.48)
6MCRB Seres Therapeutics
207.61 M
 0.00 
 5.17 
(0.02)
7DVAX Dynavax Technologies
199.95 M
 0.08 
 1.50 
 0.12 
8DTIL Precision BioSciences
174.05 M
 0.05 
 6.39 
 0.29 
9MIST Milestone Pharmaceuticals
110.42 M
 0.03 
 5.54 
 0.15 
10MIRM Mirum Pharmaceuticals
106.8 M
 0.08 
 2.52 
 0.21 
11MESO Mesoblast
88.82 M
(0.20)
 3.61 
(0.71)
12MNKD MannKind Corp
76.65 M
(0.21)
 1.86 
(0.38)
13MRSN Mersana Therapeutics
71.4 M
(0.20)
 8.70 
(1.75)
14MRUS Merus BV
68 M
 0.06 
 2.66 
 0.15 
15EQ Equillium
60.04 M
(0.05)
 7.64 
(0.37)
16DYAI Dyadic International
50.41 M
(0.10)
 3.91 
(0.38)
17MDWD Mediwound
50.4 M
(0.01)
 3.63 
(0.02)
18MTEX Mannatech Incorporated
49.88 M
(0.14)
 4.23 
(0.61)
19MEIP MEI Pharma
46.75 M
(0.03)
 1.92 
(0.05)
20MBIO Mustang Bio
42.37 M
(0.29)
 9.11 
(2.69)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets. Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.